高级检索
当前位置: 首页 > 详情页

Network Pharmacology Integrated Experimental Validation Uncover Quercetin as the Key Ingredient of Hedyotis diffusa Anti-BRCA

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Breast Surgery, Affiliated Hospital of Hebei University, Baoding, China. [2]College of Life Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Hebei University, Baoding, China. [3]School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China. [4]College of Pharmaceutical Science, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, State Key Laboratory of new Pharmaceutical Preparations and Excipients, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Hebei University, Baoding, China.
出处:
ISSN:

关键词: breast cancer Hedyotis diffusa network pharmacology quercetin

摘要:
Hedyotis diffusa, a famous Traditional Chinese Medicine (TCM), has been extensively used clinically for thousands of years. Although the therapeutic effect of Hedyotis diffusa on tumors has attracted wide attention, components, and mechanisms against breast cancer (BRCA) have not been fully understood. The study aims to explore the active components and molecular mechanisms of Hedyotis diffusa against BRCA using network pharmacology combined with experimental validation. The results of network pharmacology indicated that quercetin was the most core component of Hedyotis diffusa. BIRC5, CDK1, FOS, and HSP90AA1 were considered candidate key targets of Hedyotis diffusa against BRCA. KEGG enrichment analysis revealed that multiple cancer-related pathways are enriched, including pathways in cancer, estrogen signaling pathway, and PI3K-AKT signaling pathway, and the like. The results of in vitro experiments showed that quercetin inhibited the proliferation of both MCF-7 cells and MDA-MB-231 cells in a dose-dependent manner. Furthermore, the experimental data demonstrated quercetin may decrease the expression level of BIRC5, CDK1, and HSP90AA1 in MCF-7 cells. Overall, results of the study indicated that quercetin may play a vital role in the anti-BRCA effect of Hedyotis diffusa, and quercetin can affect the expression of BIRC5, CDK1, and HSP90AA1 in MCF-7 cells. This study may provide new evidence for the use of Hedyotis diffusa in the treatment of BRCA.© 2025 John Wiley & Sons Ltd.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2026]版:
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 生化与分子生物学 4 区 药物化学
第一作者:
第一作者机构: [1]Department of Breast Surgery, Affiliated Hospital of Hebei University, Baoding, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:15100 今日访问量:0 总访问量:960 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号